Synthetic stool transplant for C. difficile treatment

NewsGuard 100/100 Score

A synthetic mixture of intestinal bacteria could one day replace stool transplants as a treatment for Clostridium difficile (C. difficile)

A synthetic mixture of intestinal bacteria could one day replace stool transplants as a treatment for Clostridium difficile (C. difficile). C. difficile is a toxin-producing bacteria that can overpopulate the colon when antibiotics eradicate other, naturally protective bacteria living there.

"A synthetic stool transplant has a lot of potential because we can control what goes in and we can alter, change, or modify it as necessary," says Elaine Petrof, an assistant professor in the Department of Medicine at Queen's University and in the Gastrointestinal Disease Research Unit (GIDRU) at Kingston General Hospital.

Dr. Petrof and her collaborator at the University of Guelph, Emma Allen-Vercoe, believe that a stool compound made from synthetic or "purified" bacteria could significantly improve on regular stool transplants. It could eliminate the chance of transmitting an infectious disease through fecal bacteria; physicians could tailor the mixture so as to increase patient acceptance; it would be easily reproducible; and, it may appeal to both doctors and patients as a 'cleaner' therapy.

Dr. Petrof and Dr. Allen Vercoe, an anaerobic microbiologist specializing in intestinal bacteria, are working closely to develop such a therapy. The goal behind their synthetic stool project is to offer a single-dose remedy, putting an end to revolving-door hospital visits for patients with recurring symptoms. Currently, they are continuing their research before using it as a new therapy.

Dr. Petrof recently presented the project's preliminary findings at the Beneficial Microbes Conference in Noordwijkerhout, the Netherlands.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis